12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Multaq dronedarone regulatory update

EMA's CHMP recommended updating the label for Sanofi's atrial fibrillation (AF) drug Multaq dronedarone to include a contraindication against concomitant use with dabigatran. Multaq, a multichannel blocker with properties of antiarrhythmics in Vaughan-Williams classes I-IV, is approved in...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >